Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

ABSTRACT: Expression profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

PROVIDER: PRJNA596195 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR10720153.fastq.gz	Fastqsanger.gz
	SRR10720154.fastq.gz	Fastqsanger.gz
	SRR10720155.fastq.gz	Fastqsanger.gz
	SRR10720156.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

Project description:RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

| PRJNA596345 | ENA

RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

Project description:Dog breast cancer cells were infected at a multiplicity of infection of 5 for 6 hours or mock-infected (Control) for 6 hours prior to analyses by single-cell RNA sequencing. The objective was to study the distribution of host cell and viral gene expression.on the cancer cell population and to compare the effect of viral infection on these cells.

2020-10-07 | GSE142180 | GEO

Single-cell RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

Project description:Single-cell RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

| PRJNA596348 | ENA

Single-cell RNAseq profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

Project description:Dog breast cancer cells were infected at a multiplicity of infection of 5 for 6 houurs or mock-infected (Control) for 6 hours prior to analyses by single-cell RNA sequencing. The objective was to study the distribution of host cell and viral gene expression on the cancer cell population and to compare the effect of viral infection on these cells.

2020-10-07 | GSE142184 | GEO

Oncolytic efficacy of thymidine kinase-deleted vaccinia virus strain Guang9.

Project description:Oncolytic virotherapy is being developed as a promising platform for cancer therapy due to its ability to lyse cancer cells in a tumor-specific manner. Vaccinia virus has been used as a live vaccine in the smallpox eradication program and now is being potential in cancer therapy with a great safety profile. Vaccinia strain Guang9 (VG9) is an attenuated Chinese vaccinia virus and its oncolytic efficacy has been evaluated in our previous study. To improve the tumor selectivity and oncolytic efficacy, we here developed a thymidine kinase (TK)-deleted vaccinia virus based on Guang9 strain. The viral replication, marker gene expression and cytotoxicity in various cell lines were evaluated; antitumor effects in vivo were assessed in multiple tumor models. In vitro, the TK-deleted vaccinia virus replicated rapidly, but the cytotoxicity varied in different cell lines. It was notably attenuated in normal cells and resting cells in vitro, while tumor-selectively replicated in vivo. Significant antitumor effects were observed both in murine melanoma tumor model and human hepatoma tumor model. It significantly inhibited the growth of subcutaneously implanted tumors and prolonged the survival of tumor-bearing mice. Collectively, TK-deleted vaccinia strain Guang9 is a promising constructive virus vector for tumor-directed gene therapy and will be a potential therapeutic strategy in cancer treatment.

| S-EPMC5522336 | biostudies-literature

Expression profiling of dog primary mammary triple-negative breast cancer cells infected or not with a vaccinia virus deleted for the thymidine kinase gene

Project description:This SuperSeries is composed of the SubSeries listed below.

2020-10-07 | GSE142185 | GEO

Transcription profiling of human Hela cells infected with Vaccinia mutants

Project description:Samples were received from the lab of Bertram Jacobs, experiments done by Jeff Langland (langland@asu.edu). Midlog Hela cells were infected with copenhagen strain Vaccinia Virus at MOI of 5. Viral stocks were sucrose pad purified. Incubated 2, 6, and 9 hrs post infection. viral mutants include VC2 (WT), VVdeltaE3L (e3L gene deleted), VVdelta83N(83N terminal amino acids of E3L delted, protein wont bind Z-DNA), VVdelta26C (26C terminal amino acids of E3L deleted, Protein wont bind dsRNA), VVdeltaE3l-ATV(E3L replaced with eIF2alpha homolog encoded by the salamander ATV virus. Product inhibits PKR but doesnt block IFN induction),and UV (UV inactivated WT)

2007-04-01 | E-TABM-64 | biostudies-arrayexpress

Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase.

Project description:The antiviral activity of a new series of thymidine analogs was determined against vaccinia virus (VV), cowpox virus (CV), herpes simplex virus, and varicella-zoster virus. Several compounds were identified that had good activity against each of the viruses, including a set of novel 5-substituted deoxyuridine analogs. To investigate the possibility that these drugs might be phosphorylated preferentially by the viral thymidine kinase (TK) homologs, the antiviral activities of these compounds were also assessed using TK-deficient strains of some of these viruses. Some of these compounds were shown to be much less effective in the absence of a functional TK gene in CV, which was unexpected given the high degree of amino acid identity between this enzyme and its cellular homolog. This unanticipated result suggested that the CV TK was important in the mechanism of action of these compounds and also that it might phosphorylate a wider variety of substrates than other type II enzymes. To confirm these data, we expressed the VV TK and human TK1 in bacteria and isolated the purified enzymes. Enzymatic assays demonstrated that the viral TK could efficiently phosphorylate many of these compounds, whereas most of the compounds were very poor substrates for the cellular kinase, TK1. Thus, the specific phosphorylation of these compounds by the viral kinase may be sufficient to explain the TK dependence. This unexpected result suggests that selective phosphorylation by the viral kinase may be a promising new approach in the discovery of highly selective inhibitors of orthopoxvirus replication.

| S-EPMC1855528 | biostudies-literature

Vaccinia virus

Project description:Vaccinia virus Genome sequencing

| PRJNA245317 | ENA

Vaccinia virus

Project description:Vaccinia virus Raw sequence reads

| PRJNA290292 | ENA